Frequency of Atrial Fibrillation in a Large Sample of Young Adults Selected From the Spanish Working Population

Rodríguez-Capitán, Jorge; Fernández-Meseguer, Ana; Romero-González, Eva; Calvo-Bonacho, Eva; Gómez‐Doblas, Juan José; Teresa–Galván, Eduardo de

doi:10.1016/j.rec.2017.03.029

Revista Española de Cardiología (English Edition)

2018

DOI: 10.1016/j.rec.2017.03.029

|View full text |Cite

Frequency of Atrial Fibrillation in a Large Sample of Young Adults Selected From the Spanish Working Population

Jorge Rodríguez-Capitán

Ana Fernández-Meseguer²,

Eva Romero-González

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that around 80% of AF patients have nonvalvular AF (NVAF), which is defined as AF without moderate or severe mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair [ 4 , 5 ]. NVAF is associated with increased morbidity, as it may raise the risk of strokes up to five-times, which usually have more severity than those not related to AF [ 3 , 6 , 7 ]. Therefore, the prevention of systemic embolisms, even after the first episode of AF, is the cornerstone of treatment [ 7 ].…”

mentioning

confidence: 99%

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Colet,

Mainar,

Salazar-Mendiguchía

et al. 2023

J. Comp. Eff. Res.

View full text Add to dashboard Cite

Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.

show abstract

mentioning

confidence: 99%

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Colet,

Mainar,

Salazar-Mendiguchía

et al. 2023

J. Comp. Eff. Res.

View full text Add to dashboard Cite

show abstract

“…Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation and ineffective atrial contraction [1]. The prevalence of AF was 0.05% in Spanish individuals aged 18-45 years in 2018 and 4.4% in the general Spanish population aged >40 years [2][3][4]. Patients with AF may have valvular heart disease or not.…”

mentioning

confidence: 99%

Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study

et al. 2019

View full text Add to dashboard Cite

Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation. Methods: An observational, retrospective study was performed using medical records of patients who initiated apixaban or acenocoumarol between 2015 and 2017. Propensity score matching was used to match patients; stroke, systemic thromboembolism, major and minor bleeding events were compared between the matched patients. Results: Patients who were prescribed apixaban had a lower rate of systemic embolism/stroke (hazard ratio [HR] = 0.54; 95% CI: 0.38–0.78; p = 0.001), minor bleeding (HR = 0.64; 95% CI: 0.52–0.79; p < 0.001) and major bleeding (HR = 0.51; 95% CI: 0.37–0.72; p < 0.001). Conclusion: Patients prescribed apixaban for the treatment of nonvalvular atrial fibrillation had lower rates of thromboembolic events and minor/major bleeding than patients on acenocoumarol.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Frequency of Atrial Fibrillation in a Large Sample of Young Adults Selected From the Spanish Working Population

Cited by 2 publications

References 7 publications

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study

Contact Info

Product

Resources

About